0DTE WAR ROOM: BLOOD IN THE STREETS AND AI ADRENALINE
THE BLOODBATH INDEX
| Ticker | Price | Change % | RVol |
|---|---|---|---|
| $LULU | 100.61 | -17.38% | 9.3 |
| $GWRE | 162.42 | -19.93% | 3.04 |
| $FICO | 932.26 | -16.68% | 4.39 |
| $BLTE | 193.61 | +13.16% | 3.8 |
| $CBRS | 210.05 | +10.30% | 1.93 |
SAAS IS A GRAVEYARD
$LULU and $GWRE are Exhibit A and B in the 'don't catch falling knives' seminar. $LULU’s 17% crash is the reality check for a dying consumer play. Founders divorcing? Who cares. The real story is the guidance cut. If a retailer can’t maintain the narrative, their multiple gets gutted. $GWRE isn't better. You don't V-shape a 20% drop on growth deceleration. Institutions are dumping the dead weight. Avoid the dip; these stocks are radioactive until the volume profiles stabilize.
THE FICO CRACK
$FICO getting dismantled by the FHFA decision to open the door to VantageScore is the ultimate moat-busting event. The market is pricing in the end of a near-monopoly. Anyone buying this 'dip' is ignoring the regulatory reality. A 16% drop is just the appetizer. Without that exclusive lock, their $10/score revenue stream is ripe for commoditization. Don't touch until we see where the floor actually sits.
AI ADRENALINE: THE ONLY GAME IN TOWN
While the rest of the market bleeds, $CBRS and $BLTE are the only ones holding meaningful relative strength. $CBRS is sitting on a $25B backlog and OpenAI synergies—this is where the institutional money is flowing. $BLTE is riding the FDA pipeline hype. When $SPY sits at 770 with a VIX spiking 5%, you hide in the high-beta names that have genuine catalysts, not the ones selling cheap leggings or legacy software.
THE PLAY
$PATH is a dumpster fire at $15.19; don't even look at the options chain. Stick to $CBRS momentum. Watch the open. If the gap-up holds, we’re looking at a gamma squeeze that tests the $230 zone. Don't be a hero in the SaaS names. If it isn't AI, it's just baggage.
Data Source: Finance News & Real-time Market Analytics.
Disclaimer: Eachi Alpha provides independent financial analysis based on algorithmic market data. This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading securities involves significant risk. Eachi Alpha is not responsible for any financial losses or damages resulting from the use of this information. Always perform your own due diligence before making investment decisions.